These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
177 related articles for article (PubMed ID: 24828266)
1. The pharmacokinetics and acceptability of lopinavir/ritonavir minitab sprinkles, tablets, and syrups in african HIV-infected children. Musiime V; Fillekes Q; Kekitiinwa A; Kendall L; Keishanyu R; Namuddu R; Young N; Opilo W; Lallemant M; Walker AS; Burger D; Gibb DM J Acquir Immune Defic Syndr; 2014 Jun; 66(2):148-54. PubMed ID: 24828266 [TBL] [Abstract][Full Text] [Related]
2. Acceptability of lopinavir/r pellets (minitabs), tablets and syrups in HIV-infected children. Kekitiinwa A; Musiime V; Thomason MJ; Mirembe G; Lallemant M; Nakalanzi S; Baptiste D; Walker AS; Gibb DM; Judd A Antivir Ther; 2016; 21(7):579-585. PubMed ID: 27128199 [TBL] [Abstract][Full Text] [Related]
3. Population Pharmacokinetics of Lopinavir/Ritonavir: Changes Across Formulations and Human Development From Infancy Through Adulthood. Yang J; Nikanjam M; Best BM; Pinto J; Chadwick EG; Daar ES; Havens PL; Rakhmanina N; Capparelli EV J Clin Pharmacol; 2018 Dec; 58(12):1604-1617. PubMed ID: 30252146 [TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics and Safety of Zidovudine, Lamivudine, and Lopinavir/Ritonavir in HIV-infected Children With Severe Acute Malnutrition in Sub-Saharan Africa: IMPAACT Protocol P1092. Owor M; Tierney C; Ziemba L; Browning R; Moye J; Graham B; Reding C; Costello D; Norman J; Wiesner L; Hughes E; Whalen ME; Purdue L; Mmbaga BT; Kamthunzi P; Kawalazira R; Nathoo K; Bradford S; Coletti A; Aweeka F; Musoke P Pediatr Infect Dis J; 2021 May; 40(5):446-452. PubMed ID: 33464021 [TBL] [Abstract][Full Text] [Related]
5. Once- versus twice-daily lopinavir/ritonavir tablets in virologically suppressed, HIV-infected, treatment-experienced children: comparative pharmacokinetics and virological outcome after switching to once-daily lopinavir/ritonavir. Chokephaibulkit K; Nuntarukchaikul M; Phongsamart W; Wittawatmongkol O; Lapphra K; Vanprapar N; Cressey TR J Antimicrob Chemother; 2012 Dec; 67(12):2927-31. PubMed ID: 22923483 [TBL] [Abstract][Full Text] [Related]
6. Efavirenz-based simplification after successful early lopinavir-boosted-ritonavir-based therapy in HIV-infected children in Burkina Faso and Côte d'Ivoire: the MONOD ANRS 12206 non-inferiority randomised trial. Dahourou DL; Amorissani-Folquet M; Malateste K; Amani-Bosse C; Coulibaly M; Seguin-Devaux C; Toni T; Ouédraogo R; Blanche S; Yonaba C; Eboua F; Lepage P; Avit D; Ouédraogo S; Van de Perre P; N'Gbeche S; Kalmogho A; Salamon R; Meda N; Timité-Konan M; Leroy V; BMC Med; 2017 Apr; 15(1):85. PubMed ID: 28434406 [TBL] [Abstract][Full Text] [Related]
7. Steady-state pharmacokinetics of lopinavir plus ritonavir when administered under different meal conditions in HIV-infected Ugandan adults. Lamorde M; Byakika-Kibwika P; Boffito M; Nabukeera L; Mayito J; Ogwal-Okeng J; Tjia J; Back D; Khoo S; Ryan M; Merry C J Acquir Immune Defic Syndr; 2012 Jul; 60(3):295-8. PubMed ID: 22481601 [TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics of lopinavir/ritonavir crushed versus whole tablets in children. Best BM; Capparelli EV; Diep H; Rossi SS; Farrell MJ; Williams E; Lee G; van den Anker JN; Rakhmanina N J Acquir Immune Defic Syndr; 2011 Dec; 58(4):385-91. PubMed ID: 21876444 [TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics of pediatric lopinavir/ritonavir tablets in children when administered twice daily according to FDA weight bands. Bastiaans DE; Forcat S; Lyall H; Cressey TR; Hansudewechakul R; Kanjanavanit S; Noguera-Julian A; Königs C; Inshaw JR; Chalermpantmetagul S; Saïdi Y; Compagnucci A; Harper LM; Giaquinto C; Colbers AP; Burger DM; Pediatr Infect Dis J; 2014 Mar; 33(3):301-5. PubMed ID: 24356253 [TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics and acceptability of once- versus twice-daily lamivudine and abacavir in HIV type-1-infected Ugandan children in the ARROW Trial. Musiime V; Kendall L; Bakeera-Kitaka S; Snowden WB; Odongo F; Thomason M; Musoke P; Adkison K; Burger D; Mugyenyi P; Kekitiinwa A; Gibb DM; Walker AS; Antivir Ther; 2010; 15(8):1115-24. PubMed ID: 21149918 [TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics and virological efficacy after switch to once-daily lopinavir-ritonavir in treatment-experienced HIV-1-infected children. Foissac F; Urien S; Hirt D; Frange P; Chaix ML; Treluyer JM; Blanche S Antimicrob Agents Chemother; 2011 Sep; 55(9):4320-5. PubMed ID: 21746952 [TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics and tolerability of once- versus twice-daily lopinavir/ritonavir treatment in HIV-1-infected children. la Porte C; van Heeswijk R; Mitchell CD; Zhang G; Parker J; Rongkavilit C Antivir Ther; 2009; 14(4):603-6. PubMed ID: 19578247 [TBL] [Abstract][Full Text] [Related]
15. Absence of circadian variation in the pharmacokinetics of lopinavir/ritonavir given as a once daily dosing regimen in HIV-1-infected patients. van Heeswijk RP; Bourbeau M; Seguin I; Giguere P; Garber GE; Cameron DW Br J Clin Pharmacol; 2005 Apr; 59(4):398-404. PubMed ID: 15801934 [TBL] [Abstract][Full Text] [Related]
16. Sex differences in lopinavir and ritonavir pharmacokinetics among HIV-infected women and men. Umeh OC; Currier JS; Park JG; Cramer Y; Hermes AE; Fletcher CV J Clin Pharmacol; 2011 Dec; 51(12):1665-73. PubMed ID: 21233301 [TBL] [Abstract][Full Text] [Related]
17. Neither branded nor generic lopinavir/ritonavir produces adequate lopinavir concentrations at a reduced dose of 200/50 mg twice daily. Ramautarsing RA; van der Lugt J; Gorowara M; Wongsabut J; Khongpetch C; Phanuphak P; Ananworanich J; Lange JM; Burger DM; Ruxrungtham K; Avihingsanon A J Acquir Immune Defic Syndr; 2012 Jan; 59(1):55-8. PubMed ID: 22027875 [TBL] [Abstract][Full Text] [Related]
18. A Phase II/III Trial of Lopinavir/Ritonavir Dosed According to the WHO Pediatric Weight Band Dosing Guidelines. Pinto JA; Capparelli EV; Warshaw M; Zimmer B; Cressey TR; Spector SA; Qin M; Smith B; Siberry GK; Mirochnick M; Pediatr Infect Dis J; 2018 Feb; 37(2):e29-e35. PubMed ID: 29088027 [TBL] [Abstract][Full Text] [Related]
19. Paediatric abacavir-lamivudine fixed-dose dispersible tablets and ritonavir-boosted lopinavir granules in neonates exposed to HIV (PETITE study): an open-label, two-stage, single-arm, phase 1/2, pharmacokinetic and safety trial. Bekker A; Salvadori N; Rabie H; du Toit S; Than-In-At K; Groenewald M; Cressey R; Nielsen J; Capparelli EV; Lallemant M; Cotton MF; Cressey TR; Lancet HIV; 2024 Feb; 11(2):e86-e95. PubMed ID: 38296364 [TBL] [Abstract][Full Text] [Related]
20. Lopinavir dosing in HIV-infected children in the United Kingdom and Ireland. Donegan K; Doerholt K; Judd A; Lyall H; Menson E; Butler K; Tookey P; Riordan A; Shingadia D; Tudor-Williams G; Gibb DM; Walker AS; Pediatr Infect Dis J; 2013 Jan; 32(1):45-50. PubMed ID: 23076384 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]